Skeletal Dysplasia Market to Grow with a CAGR of 7.00% through 2028

The emergence of precision medicine, global collaboration, and regulatory incentives are expected to drive the Global Skeletal Dysplasia Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Skeletal Dysplasia Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Skeletal Dysplasia Market stood at USD 2803.15 million in 2022 and is anticipated to grow with a CAGR of 7.00% in the forecast period, 2024-2028. This can be attributed to regulatory incentives. Governments and regulatory agencies in various countries have recognized the need to incentivize research and development for rare diseases. Incentives may include orphan drug status, which provides financial incentives and market exclusivity for pharmaceutical companies developing treatments for rare diseases. These incentives encourage investment in research and the development of innovative therapies for skeletal dysplasia.

Moreover, advances in prenatal genetic testing are allowing for earlier and more accurate diagnosis of skeletal dysplasia during pregnancy. This empowers expectant parents with the information needed to make informed decisions about their pregnancy and prepare for the specialized care their child may require after birth. 

The growth of the market is expected to be driven by the introduction of innovative pharmaceuticals and the presence of upcoming product pipelines. For instance, Amgen Inc. is currently in the phase III clinical trial stage of developing Denosumab, a treatment for Osteogenesis Imperfecta (OI), commonly known as brittle bone disease. OI is a type of skeletal dysplasia characterized by significantly short limbs. Likewise, Merck KGaA is advancing recombinant human growth hormone (r-hGH) through phase II clinical trials for the treatment of hypochondroplasia. In parallel, BioMarin is in the process of conducting phase III clinical trials for BMN 111, a potential treatment for achondroplasia in children. Achondroplasia is a form of skeletal dysplasia that hinders the transformation of cartilage into bone.

Furthermore, the market is expected to benefit from the increased awareness of skeletal dysplasia. Online resources such as the Fetal Medicine Foundation and SKELDYS.ORG provide valuable information on the diagnosis and available treatment options for various types of skeletal dysplasias. Additionally, the emergence of novel drug therapies for treating this disorder is anticipated to contribute to market growth during the forecast period. Promising therapeutic approaches include gene therapy involving allele silencing and cell-based treatments such as mesenchymal cell and bone marrow transplantation.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Skeletal Dysplasia Market.”

Based on its treatment, the skeletal dysplasia market is segmented into medication and surgical interventions. In 2022, surgical procedures dominated the market, primarily due to their high efficacy in treating conditions like achondroplasia and HPP. The growing preference among patients for surgical interventions is expected to be a key driver for the growth of this segment.

Conversely, the medication segment is projected to experience the most rapid growth during the forecast period. This growth can be attributed to increasing efforts and initiatives aimed at the development of innovative pharmaceuticals for addressing specific types of skeletal dysplasia, such as FOP and MO.

Based on region, Europe emerged as the dominant force in the global skeletal dysplasia market in 2022. This leadership position can be attributed to the widespread adoption of surgical treatments and an increasing awareness of the disease within the region. For example, the European Skeletal Dysplasia Network (ESDD), a non-profit organization, plays a pivotal role by establishing an integrated diagnostic and research network dedicated to skeletal dysplasia. Various organizations in Europe are also actively engaged in conducting epidemiological studies aimed at raising awareness about skeletal dysplasia and providing essential information to patients and their families. An illustrative example is the European Commission's publication of a population-based epidemiological study on achondroplasia in 2019. According to data from the European Surveillance of Congenital Anomalies (EUROCAT) network, the prenatal detection rate of achondroplasia increased significantly from 36% between 1991 and 1995 to 71% between 2011 and 2015.

Looking ahead to 2028, North America is expected to experience the most rapid growth in this market. This growth can be attributed to the rising prevalence of skeletal dysplasia and increased research and development initiatives focused on the development of effective pharmaceutical treatments. For instance, according to a 2018 article published by the American Dental Association, approximately 12,000 adults and 3,000 children in the United States are affected by XLH, highlighting the need for innovative treatments.

Major companies operating in Global Skeletal Dysplasia Market are:

• BioMarin Pharmaceutical Inc
• Amgen Inc
• Merck KGaA
• Regeneron Pharmaceuticals Inc
• Alexion Pharmaceuticals Inc/MA
• Ipsen Pharma SA

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The global skeletal dysplasia market is on the brink of transformative change. Emerging trends in genomics, precision medicine, gene therapy, orphan drug development, AI diagnosis, telemedicine, patient-centric care, prenatal diagnosis, and global collaboration are poised to redefine the landscape for individuals living with skeletal dysplasia. As these trends continue to evolve, there is a promising future ahead, with the potential for more effective treatments, earlier diagnoses, and improved quality of life for those affected by these rare genetic disorders,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Skeletal Dysplasia Market By Type (Achondroplasia, Fibrodysplasia Ossificans Progressive, Hypophosphatasia, Multiple Osteochondromas, X-linked Hypophosphatemia), By Treatment (Medication, Surgery), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Skeletal Dysplasia Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Skeletal Dysplasia Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: www.techsciresearch.com